66.79 ↓ 100 JPY
11.39 ↓ 10 CNY
73.77 ↑ USD
64.10 ↑ 1000 KRW
+26° ветер 1 м/c
24 July


Pfizer's COVID-19 vaccine trial success signals breakthrough in pandemic battle

Experts said they wanted to see the full trial data, but the preliminary results looked encouraging

Photo: AP

/NOVOSTIVL/ Investors in Asian markets snapped up stocks on Tuesday on hopes of a breakthrough in the coronavirus pandemic after drugmaker Pfizer indicated its COVID-19 vaccine had proved more than 90% effective in its most widespread trial.

Japan's equity benchmark Nikkei Stock Average surged over 400 points, or 1.7%, on Tuesday morning, reaching the 25,000 threshold for the first time in 29 years. The broader Topix also jumped 1.6% and reached its highest point in nine months, recovering pre-pandemic levels.

Other Asian markets also rose, with Australia's equity benchmark up over 1% and South Korea's Kospi climbing slightly at 0.2%. The Hang Seng Index in Hong Kong climbed 1.1%.

Investors took the chance to load up on shares in companies that have been hit hard by the pandemic, such as airlines. Japan's ANA Holdings rose over 16% while in Hong Kong Cathay Pacific Airways soared more than 15%. Singapore Airlines climbed 14%.

Shares in other travel-related companies also rose, including West Japan Railway and East Japan Railway, which rose 12%.

The improved outlook for oil prices lifted CNOOC 11.8% and PetroChina by 6%. Meanwhile HSBC shares jumped 6.3% on hopes that a vaccine will allow the bank to cut bad debt provisions and boost interest income.

China's CSI 300 Index of the biggest shares traded in Shanghai and Shenzhen, fell 0.2% in early trade. The index had risen for six consecutive sessions gaining from the recovery across the second largest economy, which has managed to control the pandemic. Analysts said investors were taking gains and deploying the cash in beaten down cyclical stocks across the region.

The generally bullish sentiment followed news from U.S.-based Pfizer and German partner BioNTech that their vaccine candidate "demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection."

Ray Attrill, strategist at National Australia Bank in Sydney, said: "My fellow market analysts at NAB and BNZ (Bank of New Zealand) have often remarked that no-one wants to be short equities the day that a successful coronavirus vaccine is announced. Well, we may just have arrived at the day."

Tai Hui, Chief Asia Market Strategist, J.P. Morgan Asset Management in Hong Kong, said: "The market reaction overnight reinforces our asset allocation views in the next 6-12 months, as the global economy gradually recovers from the pandemic. A medical solution could potentially accelerate this rebound."

"The vaccine, and higher bond yields, are important catalysts for a rotation towards the pandemic laggards, such as consumer discretionary, travel, energy and commodities and financials sectors."

The Dow Jones Industrial Average closed in the U.S. on Monday with a gain of 834 points, or nearly 3%, at 29,157, having risen as much as 1,600 points at the start of trading.

While the benchmark index set a new intraday record and flirted with 30,000, momentum faded as the session went on. The broader S&P 500 index closed with a modest 1% gain.

The announcement raised hopes of light at the end of the tunnel for the U.S. economy as COVID-19 cases mount. Pfizer and BioNTech reported that the experimental vaccine was shown to be more than 90% effective, a level that Citi Healthcare analysts said "exceeds the most optimistic market expectations."

Morgan Stanley said it expects "strong Moderna data in the near term as well" for the U.S. biotech company's trials of its own COVID-19 vaccine candidate.

But others warned against hoping that a vaccine will stop the coronavirus in its tracks soon.

"Even based on the most optimistic estimates, the Pfizer vaccine will not be rolled out fast enough for large parts of the population to avoid a winter 2020-21 Wave 2," said Andrew Bishop, global head of policy research at Signum Global Advisors.

U.K. Prime Minister Boris Johnson, a COVID-19 survivor, echoed this caution.

"I just don't want to let people run away with the idea that this development today is necessarily a home run, a slam dunk, a shot to the back of the net yet," Johnson told reporters, adding that "there's a long way, I'm afraid, until we've got this thing beat."

Investors also were emboldened to take on risk by Democratic candidate Joe Biden securing enough electoral votes to win the U.S. presidency, easing uncertainty over last week's election outcome.

Biden urged Americans to take precautions.

"We could save tens of thousands of lives if everyone would just wear a mask for the next few months," he said.

The Federal Reserve in its Financial Stability Report released Monday warned that markets could still take a hit if the economic impact from coronavirus pandemic worsens in the coming months.

While most assets have remained elevated thanks to government support, signs of weakness are emerging in sectors such as commercial real estate, the report said.

"Uncertainty remains high, and investor risk sentiment could shift swiftly should the economic recovery prove less promising or progress on containing the virus disappoint," the Fed said.